INVERSAGO-PHARMA
2.12.2020 10:34:39 CET | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome, INV-101, as well as its pipeline of other peripherally-acting CB1 inverse agonists in several other indications.
“The appointment of a Chief Medical Officer is an essential element of our corporate strategy as we have entered the clinical phase with our lead compound”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “Glenn brings a broad range of relevant experiences in all aspects of drug development and regulatory interactions and I trust he will have a strong impact on the science we develop at Inversago, helping us meet our objective: developing safe and potent inverse agonists of peripheral CB1 receptors”, added Dr. Ravenelle.
“I am very excited to join Inversago and work to bring new therapies to market for patients suffering from Prader-Willi syndrome and other metabolic disorders, using a mechanism that has proven its high therapeutic potential”, said Glenn D. Crater, MD, FCCP, Chief Medical Officer of Inversago Pharma.
Dr. Crater brings more than 20 years of experience in clinical development and medical affairs, including in rare diseases. Prior to joining Inversago, Glenn held many executive positions, including Vice President, Clinical Development and Medical Affairs at Theravance Biopharma and Aerocrine, as well as Country Medical Director for GSK Canada. Glenn holds a MD degree from the University of Tennessee and is Board Certified in Internal Medicine, Pulmonary Diseases.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com .
Picture of Dr. Crater available for download at: inversago.com/en/media/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005301/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Unleash Raises $35M Led by One Peak to Help Enterprises Ship AI-driven Software Faster, Safer, and Smarter4.3.2026 15:00:00 CET | Press release
Unleash, the open-source FeatureOps company, today announced a $35 million Series B financing led by One Peak, with participation from existing investors Spark Capital, Frontline Ventures, and Firstminute Capital. The new funding will be used to accelerate product innovation and global expansion as enterprises confront the opportunities and risks of AI-accelerated software delivery. AI has dramatically accelerated software development, creating a generational opportunity for anyone in an enterprise to turn ideas, prompts, and prototypes into applications. But AI has also outpaced the systems designed to control software delivery. DORA research shows that a 25% rise in AI adoption correlates with a 7% drop in software stability. Enterprises are shipping code 2-3x faster with AI, yet outages caused by uncontrolled feature rollouts and missing kill switches are costing businesses millions in lost revenue, prolonged customer downtime, and brand damage. FeatureOps is emerging as the missing
Capcom’s Resident Evil Requiem Surpasses 5 Million Units!4.3.2026 15:00:00 CET | Press release
– Worldwide acclaim contributed to strong sales – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, surpassed 5 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304446142/en/ Resident Evil Requiem Logo Resident Evil Requiem is the latest installment in the Resident Evil series, which celebrates its 30th anniversary this month. The title successfully elevated the essence of survival horror by heightening the interplay between intense fear and exhilarating action. Resident Evil Requiem was developed using RE ENGINE, Capcom’s proprietary game engine, which allowed the company to deliver visuals in photorealistic detail, including the characters’ skin, teary eyes, and flowing hair, as well as the translucency of light. In addition, the title offers a new game experience for a broad fanbase through multiple difficulty settings that accommoda
Siren Fusion 2026: The Convergence of People, Technology and Ideas4.3.2026 14:30:00 CET | Press release
An Invitation-Only Summit for Global Intelligence, National Security and Investigative Leaders Siren today announced Siren Fusion 2026, its inaugural global summit convening senior investigators, national security leaders and AI innovators for a high-trust forum on the future of investigative intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304240853/en/ Siren Fusion 2026 is the convergence of people, technology and ideas, in Galway, Ireland. An invitation-only summit for global intelligence, national security and investigative leaders. Taking place in Galway, Ireland, Fusion is the deliberate convergence of people, technology and ideas within a national security frame. Structured as an educational and strategic forum rather than a conventional conference, Fusion 2026 focuses on the issues that now define the intelligence and law enforcement agenda: Geopolitical instability AI-driven investigative transformati
Mary Kay Goes for Gold in Global Manufacturing Standards4.3.2026 14:11:00 CET | Press release
Quality, Certified: Mary Kay Achieves ISO 22716 Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, has achieved ISO 22716 certification, the internationally recognized gold standard for cosmetic Good Manufacturing Practices (GMP), reinforcing the company’s unwavering commitment to product quality, safety, and consumer trust worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304100367/en/ Chaun Harper, Chief Supply Chain Officer at Mary Kay Inc., emphasized the broader significance of the milestone: “At Mary Kay, quality is not a checkbox – it is a promise, an operational framework, and a culture. (Photo Credit: Mary Kay Inc.) Key Data Points About Mary Kay’s Global Manufacturing: Built on 26 acres of land, Mary Kay’s state-of-the-art, Silver LEED-certified Richard R. Rogers Manufacturing and R&D Center (R3) is located in Lewisville, Texas. R3 is a $100+ million investment and is a 453,00
NelsonHall Recognizes LTM as a Leader in GenAI & Process Automation for Banking4.3.2026 13:45:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in the ‘Overall’ market segment in the NelsonHall NEAT Evaluation for GenAI & Process Automation in Banking 2025. In the NEAT framework, Leaders are vendors that demonstrate high capability relative to peers in delivering immediate client benefit while also meeting future client requirements. The recognition positions LTM among the top-performing vendors evaluated for their ability to deliver both immediate business impact and long-term innovation capability in GenAI and process automation services for the banking sector. The evaluation highlights LTM’s depth of experience in financial services, which accounts for a large portion of its overall revenues, and its focused investments in GenAI, agentic AI, and process automation capabilities delivered through its BlueVerse™ platform. LTM has digital agents dedicated to manage GenAI and process automation services, supporting banking cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom